Core Viewpoint - The ongoing conflict between Juzi Biotechnology and Huaxi Biotechnology over collagen protein content has significantly impacted Juzi's stock price, which has dropped over 64% in the past month due to allegations of false advertising and quality issues [5][7]. Group 1: Company Developments - On June 23, Juzi Biotechnology acknowledged limitations in the quality standards and testing methods of its collagen products, which are not meeting the evolving industry demands [1]. - The controversy began on May 17 when Huaxi Biotechnology criticized the market's perception of hyaluronic acid versus collagen protein, indirectly targeting Juzi's products [7]. - Following a report by influencer "Big Mouth Doctor" on May 24, which claimed Juzi's collagen product contained only 0.0177% collagen, significantly below the regulatory threshold, Juzi's market value plummeted by nearly 12 billion HKD in a single day [7][8]. Group 2: Market Impact - Juzi's flagship product, "Kefumei," experienced a drastic drop in sales rankings during the 618 shopping festival, falling from 3rd to 12th place on Tmall within a short period [8]. - Bank of America downgraded Juzi's target price from 92.7 HKD to 79 HKD due to the controversy, while maintaining a "buy" rating based on potential approvals for its injectable aesthetic products later in the year [8]. - Huaxi Biotechnology also faced challenges, with its main brand Quadi disappearing from the top 20 on Tmall, indicating a mutual decline in market performance for both companies [8].
股价跌超60%，巨子生物首次承认胶原蛋白检测存在局限性